Loading...

2,281 posters, 63 videos, 56 audios, 43 topics, 18 sessions, 6,174 authors, 2,323 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

RCOG World Congress 2025

June 23 - 25, 2025 | ExCeL London, UK

PP.0122

Reproductive Carrier Screening: Benefits for Reproduction and for Maternal Health

Part of Topic

Reproductive medicine/assisted reproduction

Reproductive Carrier Screening: Benefits for Reproduction and for Maternal Health 

Vivienne Souter (1), Eugenia Martinez Jaime (1), Samantha Leonard (1), Asma Khalil (2), Elizabeth Repass (1), Yang Wang (1), Erin M Armenti (1), Victoria Blank (1), Jessica L Saben (1), Ashley Cantu-Weinstein (1), Peter Benn (3) 

1. Natera, Inc., Austin, TX, USA 2. St George’s Hospital, City St George’s University of London, London, UK 3. UCONN Health, Farmington, CT, USA 

Introduction 

The American College of Medical Genetics and Genomics (ACMG) recommends offering all pregnant individuals and those planning pregnancy a pan-ethnic, 113-gene (‘Tier 3’) carrier screening panel. 

We reviewed our experience with this panel. 

Methods 

Retrospective study 

Cohort: women aged 18–55 with samples submitted to a commercial lab (01/2023– 08/2024) for carrier screening including ACMG-Tier 3 genes 

The Tier 3 panel comprises 113 genes (97 autosomal recessive, 16 X-linked conditions). 

Pathogenic or likely pathogenic (P/LP) variants were identified primarily via next-generation sequencing. 

We calculated carrier frequencies, and estimated at-risk and affected pregnancy rates. 

Carrier frequencies for genes relevant to maternal health and reproductive risk were also analyzed. 

Results 

62,687 samples were evaluated. 

Median maternal age was 33 years; 43% of patients were not pregnant, 34% were pregnant, and 24% were of unknown pregnancy status. 

Carrier frequency was highest for the following conditions: alpha thalassemia (1 in 13), cystic fibrosis (1 in 25), beta-hemoglobinopathies (predominantly sickle cell disease) (1 in 33), and spinal muscular atrophy (1 in 60). 

Conclusions 

56% of women screened were carriers for at least one condition on the panel. 

1 in 153 pregnancies would be expected to be affected by a condition on the panel. 

1.5% of women were at increased risk for pregnancy complications due to their carrier status. 

The results demonstrate the potential benefits of carrier screening in a racially and ethnically diverse population. 


Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.